Warfarin

Fillmore and his collaborators investigated the survival outcomes of patients with cancer-associated venous thromboembolism receiving different anticoagulation therapies. Their analysis of Veterans Affairs healthcare data demonstrated that warfarin use is associated with a 16% lower risk of mortality compared to other anticoagulants. This survival benefit was most significant in patients who maintained an international normalized ratio between 2.5 and 3.0.